Log In
Print
BCIQ
Print
Print this Print this
 

Concerta, methylphenidate

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionOnce-daily Oros controlled extended-release formulation of methylphenidate
Molecular Target Dopamine transporter
Mechanism of ActionDopamine and norepinephrine reuptake inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD); Treat attention deficit hyperactivity disorder (ADHD) in adults
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today